Avastin
Trovati 14 articoli
- Bevacizumab: VEGF neutralization can damage brain vessels
- New research at Schepens Eye Research Institute may help explain why the anticancer drug Avastin ( Bevacizumab ), which targets a growth factor responsible for creation of new blood vessels ( VEGF ), causes potentially fatal brain inflammation in certain patients. Reseachers mimicked the drug’... (Leggi Articolo)
- Microangiopathic hemolytic anemia in patients treated with Bevacizumab plus Sunitinib
- The safety and maximum tolerated dose ( MTD ) of sunitinib malate( Sutent ) in combination with Bevacizumab ( Avastin ) has been assessed in patients with metastatic renal cell carcinoma ( mRCC ) in a phase I study, exploring 3 cohorts using a fixed dose of Avastin at 10 mg/kg/IV every 2 weeks an... (Leggi Articolo)
- Bevacizumab associated with tracheoesophageal fistula
- Genentech and FDA ( Food and Drug Administration ) informed HealthCare Providers of important new safety information regarding Avastain ( Bevacizumab ). Tracheoesophageal fistula has been seen in a study combining concurrent chemotherapy and radiation plus Avastin in patients with limited-sta... (Leggi Articolo)
- Serious health problems associated with blocking angiogenesis signaling from inside cell
- Angiogenesis inhibitors that block a tumor’s development of an independent blood supply have been touted as effective cancer fighters that result in fewer side effects than traditional chemotherapy. However, a new study by researchers at UCLA’s Jonsson Cancer Center showed that one method of blo... (Leggi Articolo)
- Arterial thromboembolic events: chemotherapy with Bevacizumab increases risk
- Treatment with chemotherapy and Avastin ( Bevacizumab ), an anticancer drug, is associated with a greater risk of blood clots in patients’ arteries compared with treatment with chemotherapy only. The combination of chemotherapy and Bevacizumab has been shown to increase survival in patients ... (Leggi Articolo)
- Camptosar plus Avastin in the treatment of glioblastoma multiforme
- Brain cancer patients with the poorest prognosis, those with a type of deadly tumor known as glioblastoma multiforme, may survive longer with a drug that chokes off a tumor’s blood supply. According to a new study by researchers at Duke’s Preston Robert Tisch Brain Tumor Center, a combination ... (Leggi Articolo)
- Avastin shows encouraging results in phase II study in patients with glioblastoma multiforme
- A Phase II clinical study of Bevacizumab ( Avastin ), administered alone or in combination with Irinotecan ( Camptosar ) chemotherapy, demonstrated encouraging six-month progression-free survival and objective response rate in patients with relapsed glioblastoma multiforme, the most common and a... (Leggi Articolo)
- Lung cancer: ICAM, a new predictor for treatment response and survival
- Researchers at the Ireland Cancer Center of University Hospitals of Cleveland have found a promising, novel biomarker that may be used to predict the survival of patients with advanced lung cancer and their response to treatment. Afshin Dowlati at the Ireland Cancer Center found that patients ... (Leggi Articolo)
- Bevacizumab extends survival in non-small cell lung carcinoma
- An interim analysis of a Phase III study of Avastin ( Bevacizumab ) in combination with Paclitaxel and Carboplatin in advanced, non-small cell lung cancer ( NSCLC ) met its primary efficacy endpoint of improving overall survival, or a reduction in the risk of death, compared to chemotherapy alo... (Leggi Articolo)
- Cancer: Cetuximab shows promise
- The results of several clinical studies of Cetuximab ( Erbitux ) have been presented at the American Society of Clinical Oncology ( ASCO ) 41st Annual Meeting. Irinotecan-refractory metastatic colorectal cancer Findings were presented of a randomized Phase II trial conducted by the Natio... (Leggi Articolo)
- Metastatic breast carcinoma: Paclitaxel and Bevacizumab in first-line
- A study of Bevacizumab ( Avastin ) plus Paclitaxel chemotherapy in first-line metastatic breast cancer met its primary efficacy endpoint of improving progression-free survival, compared to chemotherapy alone. Results from an interim analysis of this study showed that patients receiving Bevac... (Leggi Articolo)
- First-line treatment of non-squamous, non-small cell lung carcinoma: Bevacizumab plus chemotherapy improves survival
- Data from a study ( E4599 ) of Bevacizumab ( Avastin ) plus Paclitaxel and Carboplatin in first-line non-squamous, non-small cell lung cancer ( NSCLC ) showed the study met its primary efficacy endpoint of improving overall survival. Bevacizumab is a therapeutic antibody designed to inhibit Va... (Leggi Articolo)
- Herceptin plus chemotherapy improves disease-free survival in early breast cancer
- The therapy Herceptin with chemotherapy in patients with early stage breast cancer significantly increases disease-free survival time in women who test positive for a genetic mutation. The study also tested Herceptin with a chemotherapy combination that eliminated Adriamycin, an anthracycline ... (Leggi Articolo)
- Metronomic chemotherapy plus antiangiogenesis drug has activity in advanced breast cancer
- Chemotherapy given in low, frequent doses – a novel strategy called "metronomic" delivery – achieved partial shrinkage of disease in some advanced breast cancer patients when given concurrently with an angiogenesis inhibitor. In a pilot study of 55 patients, the combination of low-dose chemot... (Leggi Articolo)
